What's Keeping CAR T-Cell Therapies From the Outpatient Setting?

Darcy Lewis
Published: Wednesday, Mar 13, 2019
Andre Goy, MD
Andre Goy, MD
Chimeric antigen receptor (CAR) T-cell therapies have been commercially available for less than 2 years. In that short time, they have fundamentally improved the prognosis for many patients with lymphoma and leukemia. Although these therapies were initially conceived of and developed as inpatient therapies, interest is growing in extending CAR T-cell therapies to the outpatient setting.

 

Table. Oncologists' Perceptions About Toxicity and Management of CAR T-cell Therapy

Table.  Oncologists' Perceptions About Toxicity and Management of CAR T-cell Therapy
AE indicates adverse effects; CAR, chimeric antigen receptor.
 
Patients infused still require monitoring for up to a month, and “some patients, especially those with a low disease burden, do not require hospital admission at all,” the authors wrote, adding that the "large majority" of CAR T-cell infusions performed at the Fred Hutchinson Cancer Research Center in Seattle, Washington, and Children's Hospital of Philadelphia in Pennsylvania occur in the outpatient setting. For patients treated with CD28 CAR T-cell therapy, initial hospital stays of up to 7 days have proved necessary. CAR T cells “have not fully moved into the outpatient setting,” agreed Andre Goy, MD, MS, chairman and director of the John Theurer Cancer Center in Hackensack, New Jersey. "It’s an ongoing process."
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x